Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661542 · ClinicalTrials.gov registry record · Phase 1
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT02661542: Completed Phase 1 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
NCT02661542 is a Phase 1 study that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 106 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661542, a Phase 1 study, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Cohort 2 will include subjects with another tumor type enrolled in the Phase 1 dose-escalation phase who have demonstrated Clinical Benefit by Week 16.
Primary Outcome
Safety and tolerability assessed by number of subjects with adverse events (AEs), and serious adverse events. (SAEs)
Interventions
- DRUG FF-10502-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-01 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 1 |
What the finished NCT02661542 record still lists
NCT02661542 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 1 intervention - of which FF-10502-01 is the first listed.
NCT02661542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02661542 about?
NCT02661542 is a clinical study titled "Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas". A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Coh...
What is the current status of trial NCT02661542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2016-01. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT02661542?
The interventions under investigation include: FF-10502-01 (DRUG).
Who is sponsoring clinical trial NCT02661542?
This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02661542's enrollment target sits among peer trials
106 531st of 2000 higher than 1,468 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia